
A
Relative Expression (10^3-fold)
1000
800
3
2
1
0
SGLT1
SGLT2
Not detectable
H1299
PC3
Human Kidney
B
$[H^3]$-2DG uptake (% of control)
1.5
1.0
0.5
0.0
**
***
0
10
30
Dose (μM)
Canagliflozin
Dapagliflozin
C
Cell Proliferation (% of control)
1.5
1.0
0.5
0.0
0.75 mM Glucose
11 mM Glucose
0
10
20
30
90
100
Canagliflozin Dose (μM)
D
Cell Proliferation (% of control)
1.5
1.0
0.5
0.0
11 mM Glucose
11 mM Glucose + 2 mM Pyruvate
11 mM Glucose + 25 μM Acetate
0
10
20
30
90
100
Canagliflozin Dose (μM)
E
H1299
Cell Proliferation (% of control)
1.25
1.00
0.75
0.50
0.25
0.00
####
11 mM Glucose, No Galactose
10 mM Galactose, No Glucose
IC50 = 35.96 μM
IC50 = 19.55 μM
0
10
20
30
90
100
Canagliflozin Dose (μM)

Figure S2 – Canagliflozin inhibits 2-DG uptake independent of SGLTs in PC3 cells

(A) mRNA expression of SGLT1 and SGLT2 in PC3 and H1299 cells corrected to housekeeper gene (18S) and compared to human kidney samples. (B) H^3-2DG uptake (pmol of H^3-2DG/mg of protein) in PC3 cells treated with Canagliflozin or Dapagliflozin for 10 minutes and expressed relative to the vehicle controls (n=3-4, in triplicate). (C) Cellular proliferation of PC3 cells maintained in 11 mM or 0.75 mM glucose and treated with Canagliflozin and expressed relative to the vehicle controls for 48h (n=3, in quadruplicate). (D) Cellular proliferation of PC3 cells maintained in 11 mM glucose and treated with Canagliflozin in pyruvate (2mM) or acetate (25μM) supplemented conditions and expressed relative to the vehicle control for 72h (n=3-4, in quadruplicate). (E) Cellular proliferation of H1299 cells maintained in 11 mM glucose or 10 mM galactose, treated with Canagliflozin and expressed relative to the vehicle controls for 72h (n=3, in quadruplicate). Results are expressed as the mean and standard error of the mean (SEM). Vehicle versus treatment ** = $p<0.01$, *** = $p<0.001$ by one-way ANOVA for B. Galactose versus Glucose #### = $p<0.0001$ by two-way ANOVA for E.